Table 2.
Oncology Characteristics of the Study Cohorts
| Entire Cohort (N = 616) | ADT (n = 150) | Non-ADT (n = 466) | P Value | ADT ≤6 Months (n = 99) | ADT >6 Months (n = 51) | p Value | |
|---|---|---|---|---|---|---|---|
| Age at diagnosis, yrs | 64.1 ± 7.5 | 65.3 ± 7.6 | 63.7 ± 7.4 | 0.022 | 65.8 ± 7.1 | 64.3 ± 8.5 | 0.268 |
| Nodal status at time of initial treatment | |||||||
| Pathologically positive | 17 (2.8) | 15 (10.0) | 2 (0.4) | <0.001 | 4 (4.1) | 11 (21.6) | 0.002 |
| Pathologically negative | 323 (52.4) | 67 (44.7) | 256 (55.0) | 44 (44.4) | 23 (45.1) | ||
| Clinically negative∗ | 276 (44.8) | 68 (45.3) | 208 (44.6) | 51 (51.5) | 17 (33.3) | ||
| Metastatic status at time of initial treatment | |||||||
| Yes | 39 (6.3) | 8 (5.3) | 31 (6.7) | 0.045 | 1 (1.0) | 7 (13.7) | 0.006 |
| No | 509 (82.7) | 117 (78.0) | 392 (84.1) | 80 (80.8) | 37 (72.6) | ||
| Unknown | 68 (11.0) | 25 (16.7) | 43 (9.2) | 18 (18.2) | 7 (13.7) | ||
| Prostate cancer risk group | |||||||
| High-risk PC (GS ≥8) | 67 (10.9) | 44 (29.3) | 23 (4.9) | <0.001 | 20 (20.2) | 24 (47.1) | 0.001 |
| Intermediate-risk PC (GS = 7) | 245 (39.8) | 90 (60.0) | 155 (33.3) | 66 (66.7) | 24 (47.1) | ||
| Low-risk PC (GS <7) | 304 (49.3) | 16 (10.7) | 288 (61.8) | 13 (13.1) | 3 (5.8) | ||
| Prostatectomy as initial therapy | |||||||
| Yes | 333 (54.1) | 37 (24.7) | 296 (63.5) | <0.001 | 17 (17.2) | 20 (39.2) | 0.001 |
| No | 278 (45.1) | 110 (73.3) | 168 (36.1) | 81 (81.8) | 29 (57.9) | ||
| Unknown | 5 (0.8) | 3 (2.0) | 2 (0.4) | 1 (1.0) | 2 (3.9) | ||
| External radiation/brachytherapy as initial therapy | |||||||
| Yes | 235 (38.2) | 109 (72.7) | 126 (27.0) | <0.001 | 81 (81.8) | 28 (54.9) | 0.001 |
| No | 376 (61.0) | 38 (25.3) | 338 (72.5) | 18 (18.2) | 20 (39.2) | ||
| Unknown | 5 (0.8) | 3 (2.0) | 2 (0.4) | 0 | 3 (5.9) | ||
| Any chemotherapy | |||||||
| Yes | 30 (4.9) | 15 (10.0) | 15 (3.2) | 0.002 | 9 (9.1) | 6 (11.8) | 0.581 |
| No | 583 (94.6) | 135 (90.0) | 448 (96.1) | 90 (90.9) | 45 (88.2) | ||
| Unknown | 3 (0.5) | 0 | 3 (0.7) | 0 | 0 | ||
| Recurrence or progression | |||||||
| Yes | 74 (12.0) | 30 (20.0) | 44 (9.4) | 0.003 | 8 (8.1) | 22 (43.1) | <0.001 |
| No | 532 (86.4) | 120 (80.0) | 412 (88.4) | 91 (91.9) | 29 (56.9) | ||
| Unknown | 10 (1.6) | 0 | 10 (2.2) | 0 | 0 | ||
| Biochemical recurrence | |||||||
| Yes | 99 (16.1) | 52 (34.7) | 47 (10.1) | <0.001 | 20 (20.2) | 32 (62.7) | <0.001 |
| No | 515 (83.6) | 98 (65.3) | 417 (89.5) | 79 (79.8) | 19 (37.3) | ||
| Unknown | 2 (0.3) | 0 | 2 (0.4) | 0 | 0 | ||
Values are mean ± SD or n (%). “Unknown” or “inconclusive” rows excluded from hypothesis tests.
GS = Gleason score; other abbreviations as in Table 1
∗
No evidence of lymph node metastasis on imaging studies or physical examination.